Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML.

Moloney JN, Jayavelu AK, Stanicka J, Roche SL, O'Brien RL, Scholl S, Böhmer FD, Cotter TG.

Oncotarget. 2017 Nov 1;8(62):105440-105457. doi: 10.18632/oncotarget.22241. eCollection 2017 Dec 1.

2.

DOCK2: A novel FLT3/ITD leukemia drug target.

Wu M, Small D, Duffield AS.

Oncotarget. 2017 Sep 30;8(51):88253-88254. doi: 10.18632/oncotarget.21390. eCollection 2017 Oct 24. No abstract available.

3.

FLT3-ITD, NPM1, and DNMT3A Gene Mutations and Risk Factors in Normal Karyotype Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients in Upper Northern Thailand

Mevatee P, Tantiworawit A, Traisathit P, Puaninta C, Mevatee U, Angsuchawan S, Bumroongkit K.

Asian Pac J Cancer Prev. 2017 Nov 26;18(11):3031-3039.

4.

Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.

Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Fröhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes SM.

Clin Cancer Res. 2018 Feb 1;24(3):608-618. doi: 10.1158/1078-0432.CCR-17-2684. Epub 2017 Nov 10.

PMID:
29127121
5.

Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.

Cagnetta A, Soncini D, Orecchioni S, Talarico G, Minetto P, Guolo F, Retali V, Colombo N, Carminati E, Clavio M, Miglino M, Bergamaschi M, Nahimana A, Duchosal M, Todoerti K, Neri A, Passalacqua M, Bruzzone S, Nencioni A, Bertolini F, Gobbi M, Lemoli RM, Cea M.

Haematologica. 2018 Jan;103(1):80-90. doi: 10.3324/haematol.2017.176248. Epub 2017 Oct 12.

6.

Molecular targeting in acute myeloid leukemia.

Lim SH, Dubielecka PM, Raghunathan VM.

J Transl Med. 2017 Aug 29;15(1):183. doi: 10.1186/s12967-017-1281-x. Review.

7.

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells.

Metts J, Bradley HL, Wang Z, Shah NP, Kapur R, Arbiser JL, Bunting KD.

Sci Rep. 2017 Jun 30;7(1):4447. doi: 10.1038/s41598-017-04796-1.

8.

A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia.

Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC.

Mol Cancer Ther. 2017 Oct;16(10):2058-2068. doi: 10.1158/1535-7163.MCT-16-0660. Epub 2017 Jun 27.

PMID:
28655785
9.

The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis.

Tsapogas P, Mooney CJ, Brown G, Rolink A.

Int J Mol Sci. 2017 May 24;18(6). pii: E1115. doi: 10.3390/ijms18061115. Review.

10.

Taking a Bad Turn: Compromised DNA Damage Response in Leukemia.

Nilles N, Fahrenkrog B.

Cells. 2017 May 4;6(2). pii: E11. doi: 10.3390/cells6020011. Review.

11.

Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation.

Tsitsipatis D, Jayavelu AK, Müller JP, Bauer R, Schmidt-Arras D, Mahboobi S, Schnöder TM, Heidel F, Böhmer FD.

Oncotarget. 2017 Apr 18;8(16):26613-26624. doi: 10.18632/oncotarget.15772.

12.

Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Rebechi MT, Pratz KW.

Leuk Lymphoma. 2017 Sep;58(9):1-11. doi: 10.1080/10428194.2017.1283031. Epub 2017 Feb 6.

PMID:
28278729
13.

Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine.

Sabnis HS, Bradley HL, Tripathi S, Yu WM, Tse W, Qu CK, Bunting KD.

Leuk Res. 2016 Nov;50:132-140. doi: 10.1016/j.leukres.2016.10.004. Epub 2016 Oct 5.

14.

DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.

Wu M, Hamaker M, Li L, Small D, Duffield AS.

Leukemia. 2017 Mar;31(3):688-696. doi: 10.1038/leu.2016.284. Epub 2016 Oct 17.

15.

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS, Freeman SD.

PLoS One. 2016 Sep 26;11(9):e0163291. doi: 10.1371/journal.pone.0163291. eCollection 2016.

16.

Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable Liability.

AbdulSalam SF, Thowfeik FS, Merino EJ.

Biochemistry. 2016 Sep 27;55(38):5341-52. doi: 10.1021/acs.biochem.6b00703. Epub 2016 Sep 13. Review.

17.

Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells.

Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT.

J Biol Chem. 2016 Oct 14;291(42):21984-22000. Epub 2016 Aug 29. Erratum in: J Biol Chem. 2016 Nov 25;291(48):25280.

18.

Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.

Bourgeais J, Ishac N, Medrzycki M, Brachet-Botineau M, Desbourdes L, Gouilleux-Gruart V, Pecnard E, Rouleux-Bonnin F, Gyan E, Domenech J, Mazurier F, Moriggl R, Bunting KD, Herault O, Gouilleux F.

Oncotarget. 2017 Jun 27;8(26):41876-41889. doi: 10.18632/oncotarget.11480.

19.

Inhibiting Mitochondrial DNA Ligase IIIα Activates Caspase 1-Dependent Apoptosis in Cancer Cells.

Sallmyr A, Matsumoto Y, Roginskaya V, Van Houten B, Tomkinson AE.

Cancer Res. 2016 Sep 15;76(18):5431-41. doi: 10.1158/0008-5472.CAN-15-3243. Epub 2016 Aug 8.

20.

Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.

Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR.

Oncotarget. 2016 Jul 26;7(30):48280-48295. doi: 10.18632/oncotarget.10209.

Supplemental Content

Support Center